高级检索
当前位置: 首页 > 详情页

High numbers of CD68+tumor-associated macrophages correlate with poor prognosis in extranodal NK/T-cell lymphoma, nasal type

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Sun Yat Sen Univ, Ctr Canc, Dept Hematol Oncol, Guangzhou 510060, Guangdong, Peoples R China [2]Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510060, Guangdong, Peoples R China [3]State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China [4]Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China
出处:
ISSN:

关键词: TUMOR-ASSOCIATED MACROPHAGES FOLLICULAR LYMPHOMA MICROENVIRONMENT SURVIVAL EXPRESSION RITUXIMAB FEATURES

摘要:
Many studies have demonstrated that tumor-associated macrophages (TAMs) were a prognostic indicator in patients with B cell lymphoma. But, we know little about the clinical significance of TAMs in extranodal natural killer/T cell lymphoma(ENKTL), nasal type. CD68 expression was detected using immunohistochemistry to determine the numbers of TAMs in 70 ENKTL patients, and the data were used to evaluate its relationship with clinicopathological features, treatment response, and prognosis. Patients with high number of infiltrated CD68+ TAMs (> 60/hpf) at diagnosis tended to have more adverse clinical characteristics. Patients with low CD68+ TAM content (< 60/hpf) at diagnosis had better overall survival (P=0.003) and progression-free survival (P=0.002) and achieved higher complete remission rates (P=0.008). Multivariate analysis revealed that CD68+ TAM content, Ki-67 index, and stage III and IV were independent prognostic factors for both OS and PFS. Using the International Prognostic Index or Korean Prognostic Index for extranodal NK/T cell lymphoma, nasal type, the majority of patients were in the low-risk category. CD68+ TAM content was helpful to differentiate the low-risk patients with different survival outcomes. Our data suggest that CD68+ TAM content at diagnosis is a powerful predictor of prognosis for ENKTL, which suggests a role for TAMs in the pathogenesis of this disease and offers new insight into potential therapeutic strategies.

基金:

基金编号: 81400159

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 3 区 医学
小类 | 4 区 血液学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 血液学
JCR分区:
出版当年[2013]版:
Q3 HEMATOLOGY
最新[2023]版:
Q2 HEMATOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者机构: [1]Sun Yat Sen Univ, Ctr Canc, Dept Hematol Oncol, Guangzhou 510060, Guangdong, Peoples R China [3]State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China [4]Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China
通讯作者:
通讯机构: [*1]Sun Yat Sen Univ, Ctr Canc, Dept Hematol Oncol, 651 Dong Feng RD East, Guangzhou 510060, Guangdong, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:23624 今日访问量:0 总访问量:1285 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)